MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$143.67
−1.56%Jul 16, 2026, 11:30 UTC
Medicus Pharma received positive FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in acute urinary retention.
Jul 15, 2026, 17:25 UTC
Merck & Co. released topline data from the Phase 3 KEYNOTE‑C93 trial showing Keytruda outperforms chemotherapy in advanced endometrial cancer.
Source:Jul 15, 2026, 07:45 UTC
Kelun-Biotech announced that its Phase 3 clinical study (OptiTROP-Lung06) of sac-TMT combined with Keytruda for first-line treatment of PD-L1-negative advanced or metastatic NSCLC met its primary endpoint.
Source:Jul 13, 2026, 17:00 UTC
Cosmos Health entered into a five-year partnership with Libytec to commercialize DIABIT-IS X in Greece, with Cosmos Health supplying the product and Libytec handling distribution and promotion.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 9, 2026, 03:47 UTC
Merck announced that the FDA granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations.
Source:Jul 2, 2026, 12:00 UTC
Lupin has appointed Bijender Vats as senior vice president and head of human resources.
Source:Jul 2, 2026, 02:30 UTC
China's Ministry of Agriculture and Rural Affairs approved the API change for Nuflor® (florfenicol injection), allowing its return to the Chinese market.
Source:Jun 29, 2026, 12:30 UTC
Merck acquired Modifi Biosciences in a deal worth up to $1.3 billion.
Source:Jun 25, 2026, 15:06 UTC
Merck received European Union approval for the combination of Keytruda and Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Source:Jun 25, 2026, 10:45 UTC
The U.S. FDA approved Merck's KEYTRUDA and KEYTRUDA QLEX, each in combination with Gilead's Trodelvy, for first-line treatment of PD-L1+ advanced triple-negative breast cancer.
Source:Jun 24, 2026, 10:45 UTC
The European Commission approved KEYTRUDA plus Padcev as a treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer.
Jun 22, 2026, 21:00 UTC
Fred Alger Management, LLC announced the quarterly rebalancing of the Alger Russell Innovation Index, effective after the close of trading on June 26, 2026, with additions and deletions of several companies.
Source:Jun 22, 2026, 10:45 UTC
Merck announced positive topline results from the Phase 3 ATLAS-UC study of tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.
Jun 18, 2026, 10:45 UTC
The U.S. FDA approved an additional indication for Merck's CAPVAXIVE vaccine in children and adolescents aged 2 through 17 at increased risk for pneumococcal disease.
Source:Jun 16, 2026, 12:00 UTC
Protillion Biosciences announced a multi-target discovery collaboration and license agreement with Merck.
Source:Jun 12, 2026, 20:10 UTC
The U.S. FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for adjuvant treatment of certain patients with clear cell renal cell carcinoma.
Source:Jun 11, 2026, 10:45 UTC
Merck Animal Health, a division of Merck & Co., has signed a definitive agreement to acquire TARGAN, a privately held biodevice company for the poultry industry, for an undisclosed price.
Jun 9, 2026, 20:36 UTC
Gilead and Merck end a lung cancer study.
Source:Jun 8, 2026, 20:30 UTC
Merck and Gilead discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study based on an external Data Monitoring Committee recommendation.
Source:Jun 8, 2026, 12:00 UTC
Rejuvenate Bio announced a strategic R&D collaboration with Merck Animal Health and a $6 million financing.
Source:Jun 1, 2026, 21:35 UTC
The Coalition for Epidemic Preparedness Innovations (CEPI) announced approximately $62 million in funding to three entities to fast-track development and testing of vaccines targeting the Bundibugyo ebolavirus.
Source:Jun 1, 2026, 18:00 UTC
Merck's calderasib plus Keytruda received FDA Breakthrough Therapy designation for newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Source:
← PreviousPage 4